Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment

Published:2022-10-23 Issue:12 Volume:42 Page:1387-1402
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Yan Chen‐hua¹²³,Wang Yu¹²³^ORCID,Sun Yu‐qian¹²³,Cheng Yi‐fei¹²³,Mo Xiao‐dong¹²³^ORCID,Wang Feng‐rong¹²³,Chen Yu‐hong¹²³,Zhang Yuan‐yuan¹²³,Han Ting‐ting¹²³,Chen Huan¹²³,Xu Lan‐ping¹²³,Zhang Xiao‐hui¹²³,Liu Kai‐yan¹²³,Huang Xiao‐jun¹²³⁴^ORCID

Affiliation:

1. Peking University Peoples Hospital Peking University Institute of Hematology Beijing 100044 P. R. China

2. National Clinical Research Center for Hematologic Disease Beijing 100044 P. R. China

3. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing 100044 P. R. China

4. Peking‐Tsinghua Center for Life Science Beijing 100044 P. R. China

Funder

National Basic Research Program of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12376

Reference37 articles.

1. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

2. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

3. Analysis of the Global Burden of Disease study highlights the trends in death and disability‐adjusted life years of leukemia from 1990 to 2017

4. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party ( ALWP ) of the European group for blood and marrow transplantation (EBMT)

5. Fludarabine‐treosulfan compared to thiotepa‐busulfan‐fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT);Saraceni F;J Hematol Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study;Stem Cell Research & Therapy;2024-01-29

2. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them;Expert Review of Hematology;2023-11-21

3. Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study;Annals of Hematology;2023-09-08

4. Venetoclax‐based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy;European Journal of Haematology;2023-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3